Nurulimab

DB18946InvestigationalProtein Based Therapies

Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in Subjects With Unresectable/metastatic...

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4
Curator reviewed
Also known as: Anti-ctla4 mab (biocad)
Code names: BCD-145

Resolves to

Compound

UNII894KSI08XKCAS2168561-20-2

Clinical / RWD

ATCL01FY03

Targets

P16410CTLA4

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 3 drug categories

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nurulimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account